Events

GPAI Paris w/ Joanna Shields

Our CEO Joanna Shields, joins international AI experts from civil society, academia, industry and government at the Global Partnership on Artificial Intelligence (GPAI) Summit in Paris.

This important occasion offers GPAI experts and member governments to showcase recent developments from GPAI working groups in order to discuss how their collective efforts can be best harnessed to advance the responsible development and utilization of AI.

Aiming to engage external partnerships as well, the public-facing event will include reporting on ten working group study topics from the 2021 work plan, as well as additional reflection sessions facilitated by France as the host country.

About GPAI

Launched in June 2020, GPAI ("gee-pay") is a multistakeholder initiative bringing together leading experts from science, industry, civil society, international organizations and government that share values to bridge the gap between theory and practice on AI by supporting cutting-edge research and applied activities on AI-related priorities.

GPAI aims to provide a mechanism for sharing multidisciplinary research and identifying key issues among AI practitioners, with the objective of facilitating international collaboration, reducing duplication, acting as a global reference point for specific AI issues, and ultimately promoting trust in and the adoption of trustworthy AI.

Through the collaboration within our working groups, GPAI assesses – on a comprehensive, objective, open, and transparent basis – the scientific, technical, and socio-economic information relevant to understanding AI impacts, encouraging its responsible development and options for adaptation and mitigation of potential challenges.

Watch the public conference live here →
More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022